This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aung, L. Articles by Meyers, P. A. Search for Related Content PubMed PubMed Citation Articles by Aung, L. Articles by Meyers, P. A. Related Articles Related Correspondence

Metachronous Skeletal Osteosarcoma in Patients Treated with Adjuvant and Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma

From the Department of Pediatrics, Department of Surgery, Department of Biostatistics, and Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Paul A. Meyers, MD, Memorial Sloan-Kettering Cancer Center, Department of Pediatrics, PO Box 139, 1275 York Avenue, New York, NY 10021; email: meyersp{at}mskcc.org.

Purpose: The prognosis for patients who develop metachronous skeletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limited to the lungs. We investigated the incidence and outcome of metachronous skeletal OS after initial treatment of the primary tumor.

Patients and Methods: Twenty-three (median age 18.7 years) of 426 patients with nonmetastatic, high-grade primary OS treated at Memorial Sloan-Kettering Cancer Center (New York, NY) between February 1973 and May 2000 developed metachronous skeletal OS. Initial therapy included combination chemotherapy and surgery. Treatment of subsequent relapses consisted of chemotherapy or radiation alone or surgery with or without additional individualized chemotherapy.

Results: The median time from the diagnosis of primary OS to the development of metachronous OS was 1.4 years (range, 0.2 to 11.3 years). Median survival was 1.5 years (95% confidence interval [CI], 0.8 to 6.9 years). Two- and 5-year postmetachronous overall survival was 43.5% (95% CI, 23.2% to 63.7%) and 33% (95% CI, 13% to 53%), respectively. At last follow-up (range, 0.1 to 12.8 years), five (30.4%) patients were alive with no evidence of disease (range, 1.7 to 12.8 years; median, 4.4 years). For 11 patients who developed metachronous OS 24 months or more from initial diagnosis, 5-year postmetachronous survival rate for patients receiving combined modality versus monotherapy was 83% (95% CI, 54% to 100%) and 40% (95% CI, 0% to 83%), respectively.

Conclusion: In a small subset of patients who developed late metachronous OS, combined-modality therapy with surgery and aggressive chemotherapy may result in long-term postmetachronous survival. This implies that principles used in treatment of primary OS may be applied to patients with late metachronous skeletal OS.

Related Correspondence

• Metachronous Skeletal Osteosarcoma After Therapy
  Norman Jaffe
  JCO 2004 22: 1524 [Full Text]

This article has been cited by other articles:

				M. J. Hicks, J. R. Roth, C. A. Kozinetz, and L. L. Wang Clinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome J. Clin. Oncol., February 1, 2007; 25(4): 370 - 375. [Abstract] [Full Text] [PDF]

				B. Kempf-Bielack, S. S. Bielack, H. Jurgens, D. Branscheid, W. E. Berdel, G. U. Exner, U. Gobel, K. Helmke, G. Jundt, H. Kabisch, et al. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS) J. Clin. Oncol., January 20, 2005; 23(3): 559 - 568. [Abstract] [Full Text] [PDF]

				N. Jaffe Metachronous Skeletal Osteosarcoma After Therapy J. Clin. Oncol., April 15, 2004; 22(8): 1524 - 1524. [Full Text] [PDF]